Damodar Sharat, Ma David D, Ragg Scott J, Chang Annabella, Hwang William Yk, Ho Aloysius Yl, Srivastava Alok
Dept of Haematology and BMT, Mazumdar shaw medical center, Narayana health city, India.
Department of Haematology and BM Transplant, St Vincent's Hospital Sydney, NSW, Australia.
Blood Cell Ther. 2021 Oct 14;4(Spec Edition):S14-S19. doi: 10.31547/bct-2021-015.
Standardization and formal accreditation of practices related to hematopoietic stem cell transplantation (HSCT) and therapies using hematopoietic-derived cellular products aim to promote quality in clinical and laboratory practice and provide knowledge to all stakeholders of centers. This article refers to three aspects of these processes starting with the importance of accurate viable CD 34 enumeration in HSCT. A highly accurate method of enumeration and a robust EQAS program is required, especially during the current COVID-19 pandemic. The second section shares experiences with FACT-JACIE accreditation at the Singapore General Hospital demonstrating how accreditation is part of continuous improvement and not only a destination. This journey can be difficult in many HSCT centers of low- and middle-income countries (LMICs) because of the intensive and rigorous requirements of the internationally accredited models. Hence, in LMICs, a staged movement toward establishing such standards must be considered. This approach is presented in the third section of the article with data on the current situation in countries reporting to the APBMT registry.
造血干细胞移植（HSCT）及使用造血来源细胞产品的治疗相关操作的标准化和正式认证旨在提升临床和实验室实践的质量，并为各中心的所有利益相关者提供知识。本文从HSCT中准确的活CD 34计数的重要性开始，阐述了这些过程的三个方面。需要一种高度准确的计数方法和一个强大的外部质量评估计划，尤其是在当前的新冠疫情期间。第二部分分享了新加坡总医院FACT-JACIE认证的经验，展示了认证如何成为持续改进的一部分，而不仅仅是一个目标。由于国际认可模式的严格要求，在许多低收入和中等收入国家（LMICs）的HSCT中心，这一过程可能会很困难。因此，在LMICs中，必须考虑分阶段朝着建立此类标准迈进。本文第三部分介绍了这种方法，并提供了向亚太骨髓移植登记处报告的国家的现状数据。
